FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements

Global incidence of and trends in intrahepatic and extrahepatic cholangiocarcinoma from 1993 to 2012

(2020) Andrea A. Florio et al.   CANCER

Relationship between hyperphosphatemia with infigratinib (BGJ398) and efficacy in FGFR3-altered advanced/metastatic urothelial carcinoma (aUC).

(2020) Yung Lyou et al.   JOURNAL OF CLINICAL ONCOLOGY

Second-line therapies in advanced biliary tract cancers

(2020) Sri Harsha Tella et al.   LANCET ONCOLOGY

FOENIX-CCA2: A phase II, open-label, multicenter study of futibatinib in patients (pts) with intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 gene fusions or other rearrangements.

(2020) Lipika Goyal et al.   JOURNAL OF CLINICAL ONCOLOGY

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study

(2020) Ghassan K Abou-Alfa et al.   LANCET ONCOLOGY

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

(2020) Phillip C. C. Liu et al.   PLoS One

Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program

(2019) Markus Moehler et al.   BMC CANCER

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

(2019) Matthew C. H. Ng et al.   HEPATOBILIARY SURGERY AND NUTRITION

AB051. P-19. A phase II study of infigratinib (BGJ398) in previously-treated advanced cholangiocarcinoma containing FGFR2 fusions

(2019) Milind Javle et al.   HEPATOBILIARY SURGERY AND NUTRITION

Surgery For Cholangiocarcinoma

(2019) Umberto Cillo et al.   LIVER INTERNATIONAL

Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma

(2019) Paola Bertuccio et al.   JOURNAL OF HEPATOLOGY

Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review

(2019) Yuki Kitano et al.   AMERICAN JOURNAL OF SURGERY

ABC-06 | A randomised phase III, multi-centre, open-label study of active symptom control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

(2019) Angela Lamarca et al.   JOURNAL OF CLINICAL ONCOLOGY

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

(2019) Milind M. Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.

(2019) Ian M. Silverman et al.   JOURNAL OF CLINICAL ONCOLOGY

Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).

(2019) Michele Droz Dit Busset et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnostic-therapeutic management of bile duct cancer

(2019) José María Huguet et al.   World Journal of Clinical Cases

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

(2019) Aurelien Marabelle et al.   JOURNAL OF CLINICAL ONCOLOGY

Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma

(2019) Julien Edeline et al.   JAMA Oncology

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma

(2019) Andrea Cercek et al.   JAMA Oncology

Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention

(2018) Maeve A Lowery et al.   CLINICAL CANCER RESEARCH

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker-driven clinical phase II AIO study

(2018) Arndt Vogel et al.   EUROPEAN JOURNAL OF CANCER

Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma

(2018) Milind Javle et al.   JOURNAL OF CLINICAL ONCOLOGY

Trends in Incidence and Factors Affecting Survival of Patients With Cholangiocarcinoma in the United States

(2018) Shiva Kumar R. Mukkamalla et al.   Journal of the National Comprehensive Cancer Network

625PDPembrolizumab for advanced biliary adenocarcinoma: Results from the multicohort, phase II KEYNOTE-158 study

(2018) M Ueno et al.   ANNALS OF ONCOLOGY

Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study

(2018) Jean-Marc Phelip et al.   DIGESTIVE AND LIVER DISEASE

Cholangiocarcinoma: Current Knowledge and New Developments

(2017) Boris Blechacz   Gut and Liver

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

(2017) Dung T. Le et al.   SCIENCE

Macroscopic types of intrahepatic cholangiocarcinoma and the eighth edition of AJCC/UICC TNM staging system

(2017) Ze-Wu Meng et al.   Oncotarget

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH -Mutant Molecular Profiles

(2017) Farshad Farshidfar et al.   Cell Reports

A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study

(2016) John Bridgewater et al.   BMC CANCER

Biliary cancer: Utility of next-generation sequencing for clinical management

(2016) Milind Javle et al.   CANCER

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

(2016) Jesus M. Banales et al.   Nature Reviews Gastroenterology & Hepatology

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

(2015) Juan W Valle et al.   LANCET ONCOLOGY

A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study

(2014) A. Santoro et al.   ANNALS OF ONCOLOGY

Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme

(2014) M. Moehler et al.   EUROPEAN JOURNAL OF CANCER

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial

(2014) David Malka et al.   LANCET ONCOLOGY

Mutation Profiling in Cholangiocarcinoma: Prognostic and Therapeutic Implications

(2014) Chaitanya R. Churi et al.   PLoS One

SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

(2011) Anthony B. El-Khoueiry et al.   INVESTIGATIONAL NEW DRUGS

Gemcitabine and oxaliplatin with or without erlotinib in advanced biliary-tract cancer: a multicentre, open-label, randomised, phase 3 study

(2011) Jeeyun Lee et al.   LANCET ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE